Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden

References

• Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011;66:1673–86.
   PubMed Web of Science ®Google Scholar
• Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010;14:1–21.
   PubMedGoogle Scholar
• Duberg A, Janzon R, Bäck E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill 2008;13:pii:18882.
   Google Scholar
• Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013;11:482–96.
   PubMed Web of Science ®Google Scholar
• Nakano T, Lau GMG, Lau GML, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 2012;32:339–45.
   PubMed Web of Science ®Google Scholar
• Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Concensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962–73.
   PubMed Web of Science ®Google Scholar
• Alexopoulou A. Genetic heterogeneity of hepatitis C virus and its clinical significance. Ann Gastroenterol 2001;14: 261–72.
   Google Scholar
• Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014;34(Suppl 1):69–78.
   PubMedGoogle Scholar
• Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antivir Res 2013;99:12–17.
   PubMed Web of Science ®Google Scholar
• Belda O, Targett-Adams P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res 2012;170:1–14.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983–992.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–888.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34–44.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad F, Brainard D, Hyland R, An D, Symonds W, et al. Sofosbuvir in combination with PegIFN and ribavirin for 764 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-765 experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Presented at the 64rd annual meeting of the AASLD, Washington DC, USA; 2013.
   Google Scholar
• Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 2013;8:1930–40.
   PubMed Web of Science ®Google Scholar
• Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96–100.
   PubMed Web of Science ®Google Scholar
• Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, Svarovskaia ES, et al. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci USA 2011;108:20509–13.
   PubMed Web of Science ®Google Scholar
• Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, Meyer SD, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013;87:1544–53.
   PubMed Web of Science ®Google Scholar
• Danielsson A, Palanisamy N, Golbob S, Yin H, Blomberg J, Hedlund J, et al. Transmission of hepatitis C virus among intravenous drug users in the Uppsala region of Sweden. Infect Ecol Epidemiol 2014;Jan 15:4.
   Google Scholar
• HCV Phenotype working group, HCV drug development advisory group. Clinically relevant HCV drug resistance mutations figure and tables. Ann Forum Collab HIV Res 2012;14:1–10.
   Google Scholar
• Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antivir Res 2014;108:181–91.
   PubMed Web of Science ®Google Scholar
• Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010;54:3641–50.
   PubMed Web of Science ®Google Scholar
• Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, Mondal R, et al. Antiviral activity and resistance profiles for ABT-267, a novel HCV NS5A inhibitor, in vitro and during 3-day monotherapy in HCV genotype-1 (GT1)-infected treatment-naïve subjects. Abstract 1881 presented at the 63rd annual meeting of the AASLD, Boston, USA; 2012.
   Google Scholar
• Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 2012;57: 611–13.
   PubMedGoogle Scholar
• Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447–62.
   PubMed Web of Science ®Google Scholar
• McCormick AL, Wang L, Garcia-Diaz A, Macartney MJ, Webster DP, Haque T. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4. Antivir Ther 2015;20:81–5.
   PubMedGoogle Scholar
• Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients. Virol J 2013;10:355.
   PubMed Web of Science ®Google Scholar
• Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 2013;57:13–18.
   PubMed Web of Science ®Google Scholar
• Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012;26:487–503.
   PubMed Web of Science ®Google Scholar
• Wang C, Huang H, Valera L, Sun JH, O’Boyle DR 2nd, Nower PT, et al. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother 2012;56: 1350–8.
   PubMed Web of Science ®Google Scholar
• McPhee F. Phenotypic assay: technical and translational considerations. Presented at the 10th HCV DrAG meeting: issues in HCV drug development, Amsterdam, The Netherlands; 2013.
   Google Scholar
• Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013;58:646–54.
   PubMed Web of Science ®Google Scholar
• Everson GT, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Hawkins T, et al. All-oral combination of daclatasvir, dsunaprevir, and BMS-791325 for HCV genotype 1 infection. Abstract 25 presented at the 21st annual meeting of the CROI, Boston, USA; 2014.
   Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–21.
   PubMed Web of Science ®Google Scholar
• Dvory-Sobol H, Doehle B, Svarovskaia E, McCarville JF, Pang P, Afdhal N, et al. The prevalence of HCV NS5A, nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir/sofosbuvir ± RBV in the phase 3 ION Studies. Antivir Ther 2014;19(Suppl 1):A38. Available at: http://www.natap.org/2014/ResisWksp/ResisWksp_07.htm
   Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 Phase 3 study. Hepatology 2015 Jan 23 [Epub ahead of print].
   Google Scholar